EMA/PE/0000225846 - paediatric investigation plan

Ixazomib

Key facts

• Invented name:
  Ninlaro
• Active substance:
  Ixazomib
• Therapeutic area:
  Blood and lymphatic system disorders
• Decision number:
  EMA/PE/0000225846
• PIP number:
  EMA/PE/0000225846
• Pharmaceutical form(s):
  • Powder for solution for injection or infusion
  • Capsule, hard
• Condition(s) / indication(s):
  • Treatment of lymphoid malignancies (excluding multiple myeloma)
  • Treatment of Multiple Myeloma
• Route(s) of administration:
  • Intravenous use
  • Oral use
  • Gastric use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  14/04/2025
• Compliance check done:
  No